Evidence map›Paper›PMID 31069614›Full record

ArticleMolecular biology reports2019

The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer.

Mukaddes Avsar, Makbule Tambas, Zubeyde Yalniz, Demet Akdeniz, Seref Bugra Tuncer, Seda Kilic, Ozge Sukruoglu Erdogan, Rumeysa Ciftci, Nergiz Dagoglu, Sezai Vatansever and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Lung Inflammatory Phenotype in Mice Deficient in Fibulin-2 and ADAMTS-12.International journal of molecular sciences · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mukaddes AvsarDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Makbule TambasDepartment of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Zubeyde YalnizDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Demet AkdenizDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Seref Bugra TuncerDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Seda KilicDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Ozge Sukruoglu ErdoganDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey.
Rumeysa CiftciDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Nergiz DagogluDepartment of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Sezai VatanseverDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Hulya YaziciDepartment of Cancer Genetics, Institute of Oncology, Istanbul University, Capa - Fatih, 34093, Istanbul, Turkey. hulyayazici67@gmail.com.
Istanbul University · TR

Funding

Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi 24255
6 · The paper itself

Abstract

The Fibulins are a recently discovered family of extracellular matrix proteins. In this study, expression levels of the fibulin-2 (FBLN2) gene and its role in the formation of different metastatic foci were investigated in lung cancer patients. We analyzed 106 lung cancer patients and eight paraffin-embedded tissues, and 27 ethnical-, age- and sex-matched healthy controls for expression levels of the FBLN2 gene. cDNAs obtained from the enriched epithelial cells of peripheral blood lymphocytes and tumor tissues of patients were amplified with specific primers for the target FBLN2 gene and HPRT1 housekeeping gene using quantitative real-time polymerase chain reaction. FBLN2 gene expression levels of the enriched epithelial cells of peripheral blood lymphocytes were found to be decreased approximately twofold in all subsets of patients compared to healthy controls. Our results indicate a significant difference between patient subgroups and controls [F(4.124) = 14.846, p0.05] among patient subgroups: bone metastases versus non-metastatic groups (p = 0.997), bone versus brain metastases (p = 0994), bone metastases versus two primary tumors (p = 0.999), brain metastases versus two primary tumors (p = 0.999), brain metastases versus non-metastatic (p = 0.755), non-metastatic versus two primary tumors (p = 0.996), non-metastatic versus all other metastatic patients (p = 0.731). Moreover, we found a 50-fold upregulation of FBLN2 gene expression in paraffin-embedded tissues compared with the enriched epithelial cells of peripheral blood lymphocytes of patients. In the study, the enriched epithelial cells of peripheral blood lymphocytes of decreased FBLN2 expression was found to be correlated with metastasis. The fibulin-2 molecules might induce the metastatic potential through interaction with the other molecules in the microenvironment, nevertheless, it is needed further research whether the importance of FBLN2 on lung cancer oncogenesis and as a biomarker for metastatic lung cancer.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesCell CountCell-Free Nucleic AcidsCell MovementCell ProliferationFemaleFibrillin-2HumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisReal-Time Polymerase Chain ReactionTranscriptomeBiomarkers, TumorCell-Free Nucleic AcidsFBN2 protein, humanFibrillin-2ctRNAFibulin-2 (FBLN2)Gene expressionLung cancerMetastasis

Identifiers

PMID31069614
OpenAlexW2944104697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.